Colobreathe (colistimethate sodium; Allergan) is a dry powder inhaler formulation of the antibiotic colistimethate sodium that is approved for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Colistimethate belongs to the polymyxin class of antibiotics, which interact with lipopolysaccharide molecules in the outer membrane of Gram-negative bacteria, increasing permeability and leading to cell death. Colobreathe is delivered via the Turbospin inhaler device, which is manufactured by PH&T and allows for a simple and convenient twice-daily administration rather than a lengthy nebulization process.
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.